Quizartinib is in development for the treatment of newly diagnosed, fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute myeloid leukaemia (AML), an aggressive, type of cancer that starts in the blood-forming cells of the bone marrow, and often quickly moves into the blood as well. AML typically develops rapidly and is fatal unless treated. Mutations in the gene FLT3 are the most often present mutations in patients with AML and the FLT3-ITD subtype has poor prognosis and risk.
Quizartinib with chemotherapy for FLT3-ITD positive acute myeloid leukaemia
Quizartinib is in development for the treatment of newly diagnosed, fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute myeloid leukaemia (AML), an aggressive, type of cancer that starts in the blood-forming cells of the bone marrow, and often quickly moves into the blood as well.
Interventions:
Quizartinib (AC220)
Indications:
Acute myeloid leukaemia (AML)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2021